Pegi Ahlin Grabnar

949 total citations
28 papers, 762 citations indexed

About

Pegi Ahlin Grabnar is a scholar working on Molecular Biology, Pharmaceutical Science and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Pegi Ahlin Grabnar has authored 28 papers receiving a total of 762 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 12 papers in Pharmaceutical Science and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Pegi Ahlin Grabnar's work include Protein purification and stability (11 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Advanced Drug Delivery Systems (8 papers). Pegi Ahlin Grabnar is often cited by papers focused on Protein purification and stability (11 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Advanced Drug Delivery Systems (8 papers). Pegi Ahlin Grabnar collaborates with scholars based in Slovenia, Serbia and United States. Pegi Ahlin Grabnar's co-authors include Julijana Kristl, Iztok Grabnar, Alenka Zvonar Pobirk, Odon Planinšek, Nataša Poklar Ulrih, Ajda Ota, Branko Bugarski, Bojana Balanč, Viktor Nedović and Aleksandra Jovanović and has published in prestigious journals such as SHILAP Revista de lepidopterología, International Journal of Pharmaceutics and European Journal of Pharmaceutical Sciences.

In The Last Decade

Pegi Ahlin Grabnar

28 papers receiving 750 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pegi Ahlin Grabnar Slovenia 12 271 244 199 144 143 28 762
Martina Hermannová Czechia 18 240 0.9× 107 0.4× 215 1.1× 94 0.7× 114 0.8× 48 844
Richard A Graves United States 18 118 0.4× 226 0.9× 182 0.9× 64 0.4× 122 0.9× 44 743
Yibin Yu China 14 140 0.5× 255 1.0× 295 1.5× 194 1.3× 255 1.8× 24 851
Islam A. Khalil Egypt 20 204 0.8× 415 1.7× 405 2.0× 71 0.5× 231 1.6× 53 1.2k
Natália Noronha Ferreira Brazil 14 167 0.6× 263 1.1× 294 1.5× 217 1.5× 199 1.4× 28 757
Natallia V. Dubashynskaya Russia 15 141 0.5× 238 1.0× 209 1.1× 121 0.8× 87 0.6× 35 703
Ana Luiza Ribeiro de Souza Brazil 17 193 0.7× 320 1.3× 292 1.5× 156 1.1× 273 1.9× 32 1.0k
Ankur Bhardwaj India 12 136 0.5× 295 1.2× 247 1.2× 170 1.2× 197 1.4× 35 865
Derajram Benival India 17 277 1.0× 305 1.3× 371 1.9× 90 0.6× 208 1.5× 51 987
Katerina Goračinova North Macedonia 17 203 0.7× 556 2.3× 371 1.9× 115 0.8× 124 0.9× 47 1.1k

Countries citing papers authored by Pegi Ahlin Grabnar

Since Specialization
Citations

This map shows the geographic impact of Pegi Ahlin Grabnar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pegi Ahlin Grabnar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pegi Ahlin Grabnar more than expected).

Fields of papers citing papers by Pegi Ahlin Grabnar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pegi Ahlin Grabnar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pegi Ahlin Grabnar. The network helps show where Pegi Ahlin Grabnar may publish in the future.

Co-authorship network of co-authors of Pegi Ahlin Grabnar

This figure shows the co-authorship network connecting the top 25 collaborators of Pegi Ahlin Grabnar. A scholar is included among the top collaborators of Pegi Ahlin Grabnar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pegi Ahlin Grabnar. Pegi Ahlin Grabnar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Roškar, Robert, et al.. (2025). Additive effects of the new viscosity-reducing and stabilizing excipients for monoclonal antibody formulation. International Journal of Pharmaceutics. 674. 125451–125451. 3 indexed citations
2.
Grabnar, Pegi Ahlin, et al.. (2024). Lyophilised protein formulations as a patient-centric dosage form: A contribution toward sustainability paradigm. Acta Pharmaceutica. 74(2). 289–300. 2 indexed citations
3.
Grabnar, Pegi Ahlin, et al.. (2024). Novel strategies in systemic and local administration of therapeutic monoclonal antibodies. International Journal of Pharmaceutics. 667(Pt A). 124877–124877. 4 indexed citations
4.
Roškar, Robert, et al.. (2024). The search for novel proline analogs for viscosity reduction and stabilization of highly concentrated monoclonal antibody solutions. International Journal of Pharmaceutics. 655. 124055–124055. 9 indexed citations
5.
Grabnar, Pegi Ahlin, et al.. (2023). Subkutano apliciranje monoklonskih protiteles: pregled sestavin zdravil. SHILAP Revista de lepidopterología. 1–8. 2 indexed citations
6.
Planinšek, Odon, et al.. (2023). The effect of excipients on oral lyophilizates quality attributes. Macedonian Pharmaceutical Bulletin. 69(3). 179–180. 1 indexed citations
7.
Knutson, Daniel E., Aleksandar Kremenović, Pegi Ahlin Grabnar, et al.. (2023). Freeze-dried nanocrystal dispersion of novel deuterated pyrazoloquinolinone ligand (DK-I-56-1): Process parameters and lyoprotectant selection through the stability study. European Journal of Pharmaceutical Sciences. 189. 106557–106557. 3 indexed citations
8.
Planinšek, Odon, et al.. (2019). The formation and effect of mannitol hemihydrate on the stability of monoclonal antibody in the lyophilized state. International Journal of Pharmaceutics. 564. 106–116. 23 indexed citations
9.
Logar, Manca, et al.. (2018). Aggressive conditions during primary drying as a contemporary approach to optimise freeze-drying cycles of biopharmaceuticals. European Journal of Pharmaceutical Sciences. 122. 292–302. 43 indexed citations
10.
11.
12.
13.
Grabnar, Pegi Ahlin, et al.. (2015). Development and preclinical pharmacokinetics of a novel subcutaneous thermoresponsive system for prolonged delivery of heparin. International Journal of Pharmaceutics. 496(2). 583–592. 12 indexed citations
14.
Kristl, Julijana, et al.. (2014). Thermoresponsive polymers: Insights into decisive hydrogel characteristics, mechanisms of gelation, and promising biomedical applications. International Journal of Pharmaceutics. 472(1-2). 262–275. 206 indexed citations
15.
Grabnar, Iztok, et al.. (2013). Thermoreversible in situ gelling poloxamer-based systems with chitosan nanocomplexes for prolonged subcutaneous delivery of heparin: Design and in vitro evaluation. European Journal of Pharmaceutical Sciences. 50(1). 93–101. 56 indexed citations
16.
Grabnar, Pegi Ahlin, et al.. (2011). Structural characterization of liposomes made of diether archaeal lipids and dipalmitoyl-L-α-phosphatidylcholine. Biophysical Chemistry. 158(2-3). 150–156. 22 indexed citations
17.
Grabnar, Pegi Ahlin, et al.. (2011). Autoimmune reactivity of IgM acquired after oxidation. Redox Report. 16(6). 248–256. 7 indexed citations
18.
Grabnar, Pegi Ahlin & Julijana Kristl. (2011). The manufacturing techniques of drug-loaded polymeric nanoparticles from preformed polymers. Journal of Microencapsulation. 28(4). 323–335. 95 indexed citations
19.
Grabnar, Pegi Ahlin. (2010). The Comparison of Methods to Assess In Vitro Drug Release from Nanoparticles. Scientia Pharmaceutica. 78(3). 679–679. 1 indexed citations
20.
Pobirk, Alenka Zvonar, Julijana Kristl, Janez Kerč, & Pegi Ahlin Grabnar. (2009). High celecoxib-loaded nanoparticles prepared by a vibrating nozzle device. Journal of Microencapsulation. 26(8). 748–759. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martina Hermannová Breakdown of academic impact, for papers by Richard A Graves Breakdown of academic impact, for papers by Yibin Yu Breakdown of academic impact, for papers by Islam A. Khalil Breakdown of academic impact, for papers by Natália Noronha Ferreira Breakdown of academic impact, for papers by Natallia V. Dubashynskaya Breakdown of academic impact, for papers by Ana Luiza Ribeiro de Souza Breakdown of academic impact, for papers by Ankur Bhardwaj Breakdown of academic impact, for papers by Derajram Benival Breakdown of academic impact, for papers by Katerina Goračinova
Rankless by CCL
2026